DK1701944T3 - 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme - Google Patents

2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme

Info

Publication number
DK1701944T3
DK1701944T3 DK05726205T DK05726205T DK1701944T3 DK 1701944 T3 DK1701944 T3 DK 1701944T3 DK 05726205 T DK05726205 T DK 05726205T DK 05726205 T DK05726205 T DK 05726205T DK 1701944 T3 DK1701944 T3 DK 1701944T3
Authority
DK
Denmark
Prior art keywords
pyramidines
aryl
amino
substituted
treatment
Prior art date
Application number
DK05726205T
Other languages
Danish (da)
English (en)
Inventor
Paul E Fleming
Zhan Shi
Shaowu Chen
Jane F Schmidt
John C Reader
Neal D Hone
Jefrey P Ciavarri
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34749013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1701944(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of DK1701944T3 publication Critical patent/DK1701944T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK05726205T 2004-01-08 2005-01-10 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme DK1701944T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53489804P 2004-01-08 2004-01-08
PCT/US2005/000663 WO2005066139A2 (fr) 2004-01-08 2005-01-10 2-(amino-substituees)-4-aryl pyramidines et composes associes utiles dans le traitement de maladies inflammatoires

Publications (1)

Publication Number Publication Date
DK1701944T3 true DK1701944T3 (da) 2009-11-09

Family

ID=34749013

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05726205T DK1701944T3 (da) 2004-01-08 2005-01-10 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme

Country Status (18)

Country Link
US (2) US7732444B2 (fr)
EP (2) EP1701944B1 (fr)
JP (1) JP2007517895A (fr)
AR (1) AR047185A1 (fr)
AT (1) ATE437861T1 (fr)
AU (1) AU2005204060A1 (fr)
CA (1) CA2559888A1 (fr)
CY (1) CY1109529T1 (fr)
DE (1) DE602005015677D1 (fr)
DK (1) DK1701944T3 (fr)
ES (1) ES2330863T3 (fr)
HR (1) HRP20090572T1 (fr)
PL (1) PL1701944T3 (fr)
PT (1) PT1701944E (fr)
RS (1) RS51091B (fr)
SI (1) SI1701944T1 (fr)
TW (1) TW200533357A (fr)
WO (1) WO2005066139A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
BRPI0508230A (pt) * 2004-03-30 2007-07-17 Chiron Corp derivados de tiofeno substituìdo como agentes anti-cáncer
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
WO2007076247A1 (fr) * 2005-12-21 2007-07-05 Boehringer Ingelheim International Gmbh Dérivés de la pyrimidine utiles comme inhibiteurs de la pkc-thêta
JP5385125B2 (ja) * 2006-03-22 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
EP2529623A3 (fr) 2007-04-03 2013-03-13 E. I. du Pont de Nemours and Company Fongicides de benzène substitués
PT2215117E (pt) * 2007-10-30 2015-04-01 Genentech Inc Purificação de anticorpo por cromatografia de troca de catiões
EP2253618A1 (fr) 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Composé contenant un cycle aromatique à 6 chaînons
EP2169665B1 (fr) 2008-09-25 2018-05-02 LG Electronics Inc. Procédé et appareil de traitement de signal
WO2011083481A2 (fr) * 2010-01-11 2011-07-14 Healor Ltd. Procédé pour traiter une maladie et un trouble inflammatoires
AU2011274369A1 (en) * 2010-07-02 2012-12-06 Ventana Medical Systems, Inc. Hapten conjugates for target detection
ES2543050T3 (es) 2011-02-28 2015-08-14 Array Biopharma, Inc. Inhibidores de serina/treonina quinasa
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
SI2820009T1 (en) 2012-03-01 2018-05-31 Array Biopharma, Inc. Serine / Threonine kinase inhibitors
RU2638540C1 (ru) 2012-04-24 2017-12-14 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
BR112015004548A2 (pt) 2012-08-27 2017-08-08 Array Biopharma Inc inibidores de serina/treonina para tratamento de doenças hiperproliferativas
HRP20211855T1 (hr) 2013-03-12 2022-03-04 Vertex Pharmaceuticals Incorporated Inhibitori dnk-pk
AU2014324092B2 (en) 2013-09-18 2020-02-06 Epiaxis Therapeutics Pty Ltd Stem cell modulation II
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
CA2958704A1 (fr) 2014-08-25 2016-03-03 University Of Canberra Compositions pour moduler les cellules souches cancereuses et leurs utilisations
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
WO2023104744A1 (fr) 2021-12-06 2023-06-15 Helmholtz-Zentrum Dresden-Rossendorf E.V. Dérivés de 3-((3-([1,1'-biphényl]-3-ylméthoxy)phénoxy)méthyl)benzonitrile et utilisation associée

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698697A (en) 1995-07-19 1997-12-16 Mitsubishi Chemical Corporation 2-cyanopiperazine and method of producing the same
WO1999032121A1 (fr) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques
ATE245641T1 (de) * 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
IL143906A0 (en) 1998-12-24 2002-04-21 Aventis Pharmaceuticals Produs Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xa inhibitors
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
CA2376951A1 (fr) 1999-06-30 2001-01-04 Peter J. Sinclair Composes inhibiteurs de la kinase src
PL366110A1 (en) * 1999-08-13 2005-01-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
IL155089A0 (en) 2000-10-12 2003-10-31 Merck & Co Inc Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP4160401B2 (ja) * 2001-03-29 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ−ｊｕｎｎ末端キナーゼ（ｊｎｋ）および他のタンパク質キナーゼのインヒビター
WO2002083667A2 (fr) * 2001-04-13 2002-10-24 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases
GB0112803D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
JP2005511608A (ja) 2001-11-07 2005-04-28 エフ．ホフマン−ラ　ロシュ　アーゲー アミノピリミジン類及び−ピリジン類
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
EP1515964A1 (fr) * 2002-06-14 2005-03-23 ALTANA Pharma AG Diaminopyrimidines substitues
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
WO2004067516A1 (fr) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta
AU2004229392A1 (en) 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
BRPI0508230A (pt) * 2004-03-30 2007-07-17 Chiron Corp derivados de tiofeno substituìdo como agentes anti-cáncer
JP5097539B2 (ja) 2004-05-07 2012-12-12 アムジエン・インコーポレーテツド タンパク質キナーゼ調節剤および使用方法
MY144044A (en) 2004-06-10 2011-07-29 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006050476A2 (fr) * 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Modulateurs de canaux ioniques et leurs methodes d'utilisation
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
CN101115749B (zh) 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DE102005034821A1 (de) * 2005-07-26 2007-02-08 Fleissner Gmbh Voluminöse Faserlaminate und ihre Herstellung
TWM293131U (en) * 2006-01-10 2006-07-01 Shuen Tai Prec Entpr Co Ltd Handheld power hammer

Also Published As

Publication number Publication date
US20110071134A1 (en) 2011-03-24
EP1701944A2 (fr) 2006-09-20
AU2005204060A1 (en) 2005-07-21
WO2005066139A3 (fr) 2005-10-13
DE602005015677D1 (de) 2009-09-10
EP2123647A1 (fr) 2009-11-25
HRP20090572T1 (hr) 2010-01-31
PT1701944E (pt) 2009-11-03
US7732444B2 (en) 2010-06-08
TW200533357A (en) 2005-10-16
PL1701944T3 (pl) 2010-01-29
ES2330863T3 (es) 2009-12-16
CY1109529T1 (el) 2014-08-13
EP1701944B1 (fr) 2009-07-29
SI1701944T1 (sl) 2010-03-31
ATE437861T1 (de) 2009-08-15
AR047185A1 (es) 2006-01-11
US8268822B2 (en) 2012-09-18
US20060040968A1 (en) 2006-02-23
CA2559888A1 (fr) 2005-07-21
JP2007517895A (ja) 2007-07-05
RS51091B (sr) 2010-10-31
WO2005066139A2 (fr) 2005-07-21

Similar Documents

Publication Publication Date Title
DK1701944T3 (da) 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK2463283T3 (da) Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1849773T3 (da) Piperazinderivater til behandlingen af urininkontinens og smerte
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
DK2878297T3 (da) Lægemidler til behandling og forebyggelse af fibrotiske sygdomme
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme